Director/PDMR Shareholding

RNS Number : 1653N

Hemogenyx Pharmaceuticals PLC

30 May 2022

 

30 May 2022

Hemogenyx Pharmaceuticals plc  

("Hemogenyx Pharmaceuticals" or the "Company")

LEI 2138008L93GYU5GN6179

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.	Details of PDMR/person closely associated with them ("PCA")
a)	Name	Andrew Wright
2.	Reason for the notification
a)	Position/status	Financial Controller and Company Secretary
b)	Initial notification/ amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Full name of the entity	Hemogenyx Pharmaceuticals plc
b)	Legal Entity Identifier code	2138008L93GYU5GN6179
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of Hemogenyx Pharmaceuticals plc GB00BYX3WZ24
b)	Nature of the transaction	Standalone acquisition of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) GBP £0.0144 1,284,889
d)	Aggregated information -  Aggregated volume -  Price	Price(s) Volume(s) GBP £18,502.40 1,284,889
e)	Date of the transaction	2022-05-27
f)	Place of the transaction	London Stock Exchange XLON

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director	[e-mail]
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

END

 

 

DSHDBGDULBDDGDC